Literature DB >> 18367484

Effects of the aurora kinase inhibitors AZD1152-HQPA and ZM447439 on growth arrest and polyploidy in acute myeloid leukemia cell lines and primary blasts.

Elisabeth Walsby1, Val Walsh, Chris Pepper, Alan Burnett, Ken Mills.   

Abstract

BACKGROUND: Aurora kinases play an essential role in the orchestration of chromosome separation and cytokinesis during mitosis. Small-molecule inhibition of the aurora kinases has been shown to result in inhibition of cell division, phosphorylation of histone H3 and the induction of apoptosis in a number of cell systems. These characteristics have led aurora kinase inhibitors to be considered as potential therapeutic agents. DESIGN AND METHODS: Aurora kinase gene expression profiles were assessed in 101 samples from patients with acute myeloid leukemia. Subsequently, aurora kinase inhibitors were investigated for their in vitro effects on cell viability, histone H3 phosphorylation, cell cycle and morphology in acute myeloid leukemia cell lines and primary acute myeloid leukemia samples.
RESULTS: The aurora kinase inhibitors AZD1152-HQPA and ZM447439 induced growth arrest and the accumulation of hyperploid cells in acute myeloid leukemia cell lines and primary acute myeloid leukemia cultures. Furthermore, both agents inhibited histone H3 phosphorylation and this preceded perturbations in cell cycle and the induction of apoptosis. Single cell cloning assays were performed on diploid and polyploid cells to investigate their colony-forming capacities. Although the polyploid cells showed a reduced capacity for colony formation when compared with their diploid counterparts, they were consistently able to form colonies.
CONCLUSIONS: AZD1152-HQPA- and ZM447439 are effective apoptosis-inducing agents in acute myeloid leukemia cell lines and primary acute myeloid leukemia cultures. However, their propensity to induce polyploidy does not inevitably result in apoptosis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18367484     DOI: 10.3324/haematol.12148

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  41 in total

1.  Inhibition of Aurora kinases enhances chemosensitivity to temozolomide and causes radiosensitization in glioblastoma cells.

Authors:  Kleiton Silva Borges; Angel Maurício Castro-Gamero; Daniel Antunes Moreno; Vanessa da Silva Silveira; Maria Sol Brassesco; Rosane Gomes de Paula Queiroz; Harley Francisco de Oliveira; Carlos Gilberto Carlotti; Carlos Alberto Scrideli; Luiz Gonzaga Tone
Journal:  J Cancer Res Clin Oncol       Date:  2011-12-09       Impact factor: 4.553

Review 2.  Mitosis as an anti-cancer drug target.

Authors:  Anna-Leena Salmela; Marko J Kallio
Journal:  Chromosoma       Date:  2013-06-18       Impact factor: 4.316

Review 3.  Cell cycle kinases as therapeutic targets for cancer.

Authors:  Silvia Lapenna; Antonio Giordano
Journal:  Nat Rev Drug Discov       Date:  2009-07       Impact factor: 84.694

4.  Enhanced radiosensitivity of androgen-resistant prostate cancer: AZD1152-mediated Aurora kinase B inhibition.

Authors:  Kenneth J Niermann; Luigi Moretti; Nicholas J Giacalone; Yunguang Sun; Stephen M Schleicher; Prapaporn Kopsombut; Lauren R Mitchell; Kwang Woon Kim; Bo Lu
Journal:  Radiat Res       Date:  2011-01-11       Impact factor: 2.841

5.  A phase I trial of the aurora kinase inhibitor, ENMD-2076, in patients with relapsed or refractory acute myeloid leukemia or chronic myelomonocytic leukemia.

Authors:  Karen W L Yee; Hsiao-Wei T Chen; David W Hedley; Sue Chow; Joseph Brandwein; Andre C Schuh; Aaron D Schimmer; Vikas Gupta; Deborah Sanfelice; Tara Johnson; Lisa W Le; Jamie Arnott; Mark R Bray; Carolyn Sidor; Mark D Minden
Journal:  Invest New Drugs       Date:  2016-07-12       Impact factor: 3.850

6.  Inhibitor of Aurora Kinase B Induces Differentially Cell Death and Polyploidy via DNA Damage Response Pathways in Neurological Malignancy: Shedding New Light on the Challenge of Resistance to AZD1152-HQPA.

Authors:  Ali Zekri; Seyed H Ghaffari; Marjan Yaghmaie; Mehrdad Asghari Estiar; Kamran Alimoghaddam; Mohammad Hossein Modarressi; Ardeshir Ghavamzadeh
Journal:  Mol Neurobiol       Date:  2015-03-11       Impact factor: 5.590

Review 7.  Update on aurora kinase inhibitors in gynecologic malignancies.

Authors:  Xia Tao; Hye S Chon; Siqing Fu; John J Kavanagh; Wei Hu
Journal:  Recent Pat Anticancer Drug Discov       Date:  2008-11       Impact factor: 4.169

Review 8.  Mitotic failures in cancer: Aurora B kinase and its potential role in the development of aneuploidy.

Authors:  Katalin Hegyi; Gábor Méhes
Journal:  Pathol Oncol Res       Date:  2012-07-29       Impact factor: 3.201

Review 9.  Centrosome-associated regulators of the G(2)/M checkpoint as targets for cancer therapy.

Authors:  Yingmei Wang; Ping Ji; Jinsong Liu; Russell R Broaddus; Fengxia Xue; Wei Zhang
Journal:  Mol Cancer       Date:  2009-02-13       Impact factor: 27.401

10.  Identification of a kinase profile that predicts chromosome damage induced by small molecule kinase inhibitors.

Authors:  Andrew J Olaharski; Nina Gonzaludo; Hans Bitter; David Goldstein; Stephan Kirchner; Hirdesh Uppal; Kyle Kolaja
Journal:  PLoS Comput Biol       Date:  2009-07-24       Impact factor: 4.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.